- Silmitasertib
-
- $34.00 / 1mg
-
2025-10-14
- CAS:1009820-21-6
- Min. Order:
- Purity: 99.90%
- Supply Ability: 10g
|
| | CX-4945 Basic information |
| Product Name: | CX-4945 | | Synonyms: | 5-[(3-chlorophenyl)amino]-Benzo[c]-2,6-naphthyridine-8-carboxylic acid;CX-4945;Silmitasertib;CX-4945 Silmitasertib;CX-4945, CX4945;Silmitasertib(CX-4945);5-[(3-Chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylic acid CX-4945 (Silmitasertib);CX-4945, >=98% | | CAS: | 1009820-21-6 | | MF: | C19H12ClN3O2 | | MW: | 349.77 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1009820-21-6.mol |  |
| | CX-4945 Chemical Properties |
| Boiling point | 568.5±50.0 °C(Predicted) | | density | 1.490 | | storage temp. | Store at -20°C | | solubility | ≥103.5 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | | form | Orange powder. | | pka | 2.96±0.30(Predicted) | | color | Yellow to orange | | InChI | InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25) | | InChIKey | MUOKSQABCJCOPU-UHFFFAOYSA-N | | SMILES | C1(NC2=CC=CC(Cl)=C2)C2=C(C=NC=C2)C2=CC=C(C(O)=O)C=C2N=1 |
| | CX-4945 Usage And Synthesis |
| Uses | CX-4945 is a protein kinase CK2 inhibitor resulting in cancer cell death and prevention of proliferation. Anti-leukemia agent. | | Biological Activity | cx-4945 (silmitasertib) is a potent and selective casein kinase 2 (ck2) inhibitor with ic50 value of 1 nm. it is atp-competitive and can be taken orally [1].cx-4945 has been reported to have antiproliferative activity against a wide range of tumor cell lines. it is suggested that cx-4945 suppresses the ck2 regulated pi3k/akt signaling pathway by inhibiting akt phosphorylation at serine 129, but not by activating pten. additionally, cells treated with cx-4945 had a reduction of p21 phophorylation and an up-regulations of total p21 and p27. cx-4945 has been shown to induce cell-cycle arrest at g2/m phase in breast cancer cell line bt-474. it also causes cell-cycle arrest at g1 phase the breast cancer cell line bxpc-3) [1].in cx-4945 and bxpc-3 derived mouse xenograft model, cx-4945 induced a reduction of phos-p21 expression along with anti-carcinoma effects [1] | | in vivo | Silmitasertib (CX-4945) (25 or 75 mg/kg, p.o.) is well tolerated and demonstrated robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models[1]. | | IC 50 | CK2α: 1 nM (IC50); CK2α': 1 nM (IC50) | | references | [1] siddiqui-jain a1, drygin d, streiner n, chua p, pierre f, o'brien se, bliesath j, omori m, huser n, ho c, proffitt c, schwaebe mk, ryckman dm, rice wg,anderes k. cx-4945, an orally bioavailable selective inhibitor of protein kinase ck2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. cancer res. 2010 dec 15; 70 (24): 10288-98. |
| | CX-4945 Preparation Products And Raw materials |
|